Humira LOE Is ‘Uncharted Territory’ As Fierce Competition Expected
Q&A With AmerisourceBergen’s Biosimilar Commercialization Director Brian Biehn
Discussing the latest developments in the US biosimilars market, AmerisourceBergen’s senior director of biosimilar commercialization, Brian Biehn, talks about what we can expect from competition to Humira in 2023, how the first ophthalmology biosimilars are faring, and potential changes on the horizon at the FDA that could smooth the path to market for biosimilars sponsors.
You may also be interested in...
The biggest loss of exclusivity in pharmaceutical history is set to steal headlines in the first month of 2023, as Teva begins a new year with a new CEO.
United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.
One month after launching its Cimerli ranibizumab biosimilar to Lucentis, Coherus BioSciences’ management explained how it had stolen a march on the earlier introduced Byooviz product launched by Biogen/Samsung Bioepis.